Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Feature|Videos|September 11, 2024
Grace: Your API CDMO Partner of Choice
Bob Hughes (Research Fellow, Grace) and Brian Graves (Global Business Manager, Fine Chemicals, Grace) explain how Grace's experience as a CDMO can help customers from the lab to full-scale production.
Advertisement
Bob Hughes and Brian Graves sat down with Pharmaceutical Technology to highlight key elements of working alongside Grace. Learn more about:
- How with 40 years of experience in the CDMO space, Grace is a collaborative partner with their customers throughout the entire project, from the lab to commercial-scale production
- Grace's well-established, systematic processes for executing your next small molecule API project
- Grace’s Fine Chemical Manufacturing Services (FCMS) and the technical expertise & operational capabilities to support your next project
Advertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
Advertisement
Advertisement